Zevenbergen Capital Investments LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 142,685 shares of the biopharmaceutical company’s stock after selling 3,925 shares during the quarter. Regeneron Pharmaceuticals makes up about 2.8% of Zevenbergen Capital Investments LLC’s holdings, making the stock its 14th largest position. Zevenbergen Capital Investments LLC owned about 0.13% of Regeneron Pharmaceuticals worth $63,797,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $130,000. Sterling Investment Advisors Ltd. grew its holdings in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares during the period. FNY Partners Fund LP grew its holdings in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 200 shares during the period. IFP Advisors Inc grew its holdings in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $206,000. 66.51% of the stock is owned by institutional investors and hedge funds.

In related news, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders sold a total of 4,779 shares of company stock valued at $2,248,467 over the last quarter. Company insiders own 10.80% of the company’s stock.

REGN has been the subject of several recent analyst reports. UBS AG restated a “buy” rating and issued a $535.00 price target (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 4th. Citigroup Inc. lifted their price objective on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Credit Suisse Group reaffirmed a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $475.34.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at $384.85 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The firm has a market capitalization of $41,347.90, a P/E ratio of 33.32, a PEG ratio of 1.51 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same period in the previous year, the business earned $3.13 EPS. The business’s quarterly revenue was up 23.0% on a year-over-year basis. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Holdings Reduced by Zevenbergen Capital Investments LLC” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-holdings-reduced-by-zevenbergen-capital-investments-llc/1729048.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.